AMBU B Ambu A/S Class B

Ambu A/S: Ambu’s production exempt from Malaysian movement control order

Ambu A/S: Ambu’s production exempt from Malaysian movement control order

The Malaysian authorities have granted Ambu – as a manufacturer of medical devices – exemption from the two-week movement control order that has been declared with effect from 18 March, 2020. The nationwide movement control order is an initiative to counter the spread of Covid-19 in Malaysia.

Our role is to keep supplying hospitals around the globe with devices that help save lives and improve patient care. With the current pressure on national healthcare systems, we do our utmost to make sure that we can keep producing and delivering supplies to hospitals. Therefore, it is positive that the Malaysian authorities recognize the role we play in supporting healthcare facilities,” says Juan Jose Gonzalez, CEO of Ambu.



Contacts

Investors

Michael Højgaard, CFO, tel. , email:

Nicolai Thomsen, Investor Relations Manager, tel. , email:

Media

Mikkel Trier Wagner, Director Corporate Communications, tel. , email:

Attachment

EN
18/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch